AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Imugene Limited

$0.04 -$0.23 (-85.19%)
OTC · 14 Sep 2026 20:00 UTC
Previous Close
$0.04
Day Range
$0.04$0.05
Year Range
$0.04$0.31
Market Cap
19.59M
AVG Volume
23.07K
Trailing/Forward PE
-0.14/-
PEG ratio
0.01
Dividend Yield
-
Next Earnings Date
2027-03-03
Primary Exchange
Other OTCUS
Revenue (AUD)
-5M05M10M22 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q226 Q4
IUGNF Revenue (AUD) by quarter
PeriodRevenue (AUD)
26 Q40
26 Q20
25 Q43.14M
25 Q21.26M
24 Q4-3.1M
24 Q28.07M
23 Q46.96M
23 Q24.81M
22 Q47.62M
22 Q25.35M
Net Income (AUD)
-100M-75M-50M-25M022 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q226 Q4
IUGNF Net Income (AUD) by quarter
PeriodNet Income (AUD)
26 Q4-67.42M
26 Q2-37.81M
25 Q4-20.68M
25 Q2-48.34M
24 Q4-80.97M
24 Q2-68.72M
23 Q4-20.52M
23 Q2-17.39M
22 Q4-23.04M
22 Q2-14.83M
Operating Income (AUD)
-100M-75M-50M-25M022 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q226 Q4
IUGNF Operating Income (AUD) by quarter
PeriodOperating Income (AUD)
26 Q4-33.07M
26 Q2-40.41M
25 Q4-21.11M
25 Q2-49.83M
24 Q4-67.56M
24 Q2-86.16M
23 Q4-29.39M
23 Q2-21.91M
22 Q4-30.15M
22 Q2-20.52M
EBITDA (AUD)
-80M-60M-40M-20M022 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q226 Q4
IUGNF EBITDA (AUD) by quarter
PeriodEBITDA (AUD)
26 Q4-31.44M
26 Q2-40.06M
25 Q4-18.9M
25 Q2-48.52M
24 Q4-71.47M
24 Q2-69.15M
23 Q4-20.5M
23 Q2-21.07M
22 Q4-29.16M
22 Q2-14.1M
Cash Flows (AUD)
-60M-40M-20M022 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q226 Q4
IUGNF Cash Flows (AUD) by quarter
PeriodCash Flows (AUD)
26 Q4-18.86M
26 Q2-25.96M
25 Q4-33.73M
25 Q2-49.39M
24 Q4-46.86M
24 Q2-59.92M
23 Q4-9.16M
23 Q2-20.61M
22 Q4-20.64M
22 Q2-10.29M
EPS (AUD)
-0.4-0.3-0.2-0.1-022 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q226 Q4
IUGNF EPS (AUD) by quarter
PeriodEPS (AUD)
26 Q4-0.19
26 Q2-0.13
25 Q4-0.09
25 Q2-0.22
24 Q4-0.38
24 Q2-0.34
23 Q4-0.11
23 Q2-0.1
22 Q4-0.14
22 Q2-0.09
Expenses (AUD)
-25M025M50M75M100MR&DSG&ACapex22 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q226 Q4
IUGNF Expenses (AUD) by quarter
PeriodExpenses (AUD)
26 Q431.44M
26 Q235.2M
25 Q420.92M
25 Q261.09M
24 Q465.52M
24 Q290.73M
23 Q423.28M
23 Q221.91M
22 Q430.4M
22 Q220.53M
Cash & Debt (AUD)
050M100M150M200MCashLong Term DebtShort Term Debt22 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q226 Q4
IUGNF Cash & Debt (AUD) by quarter
PeriodCash & Debt (AUD)
26 Q42.63M
26 Q214.13M
25 Q421.94M
25 Q233.74M
24 Q494.54M
24 Q2139.39M
23 Q4153.15M
23 Q2161.91M
22 Q499.89M
22 Q2118.41M
Debt ratios
-1012322 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q226 Q4
IUGNF Debt ratios by quarter
PeriodDebt ratios
26 Q4-0.03
26 Q20.05
25 Q40.05
25 Q20.09
24 Q40.51
24 Q20.95
23 Q41.8
23 Q22.16
22 Q41.55
22 Q22.8
Margins
0%50%100%150%21 Q221 Q422 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q4
IUGNF Margins by quarter
PeriodMargins
25 Q4100%
25 Q2100%
24 Q4100%
24 Q2100%
23 Q4100%
23 Q2100%
22 Q4100%
22 Q2100%
21 Q4100%
21 Q2100%
Return on Capital
-800%-600%-400%-200%0%22 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q226 Q4
IUGNF Return on Capital by quarter
PeriodReturn on Capital
26 Q4-749.39%
26 Q2-90.34%
25 Q4-45.93%
25 Q2-76.39%
24 Q4-68.47%
24 Q2-35.27%
23 Q4-10.82%
23 Q2-8.39%
22 Q4-16.61%
22 Q2-9.78%
Shares Outstanding
0100M200M300M400M22 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q226 Q4
IUGNF Shares Outstanding by quarter
PeriodShares Outstanding
26 Q4349.06M
26 Q2291.82M
25 Q4219.53M
25 Q2217.88M
24 Q4213.95M
24 Q2202.41M
23 Q4188.91M
23 Q2180.35M
22 Q4169.77M
22 Q2159.99M
Book Value Per Share (AUD)
00.511.522 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q226 Q4
IUGNF Book Value Per Share (AUD) by quarter
PeriodBook Value Per Share (AUD)
26 Q40.03
26 Q20.14
25 Q40.21
25 Q20.29
24 Q40.55
24 Q20.96
23 Q41
23 Q21.15
22 Q40.82
22 Q20.95
Total Assets (AUD)
0100M200M300M22 Q222 Q423 Q223 Q424 Q224 Q425 Q225 Q426 Q226 Q4
IUGNF Total Assets (AUD) by quarter
PeriodTotal Assets (AUD)
26 Q423M
26 Q267.64M
25 Q483.59M
25 Q2120.92M
24 Q4151.4M
24 Q2230.42M
23 Q4197.06M
23 Q2212.54M
22 Q4147.61M
22 Q2159.45M
Free Cash Flow Yield
-1000%-750%-500%-250%0%med -256.31%Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
IUGNF Free Cash Flow Yield by quarter
PeriodFree Cash Flow Yield
Sep 26-958.12%
Sep 26-958.12%
Sep 26-962.47%
Aug 26-598.14%
Aug 26-508.1%
Aug 26-496.93%
Aug 26-539.72%
Jul 26-577.52%
Jul 26-373.13%
Jul 26-533.16%
Jul 26-495.5%
Jul 26-462.35%
Jun 26-409.5%
Jun 26-394.78%
Jun 26-459.8%
Jun 26-358.75%
May 26-479.96%
May 26-418.63%
May 26-458.72%
May 26-430.4%
May 26-420.99%
Apr 26-357.11%
Apr 26-294.65%
Apr 26-368.17%
Apr 26-332.66%
Mar 26-716.67%
Mar 26-405.05%
Mar 26-292.58%
Mar 26-373.95%
Feb 26-340.18%
Feb 26-346.72%
Feb 26-349.72%
Feb 26-348.59%
Jan 26-276.97%
Jan 26-237.22%
Jan 26-314.12%
Jan 26-241.14%
Jan 26-214.56%
Dec 25-258.27%
Dec 25-260.01%
Dec 25-266.34%
Dec 25-287.25%
Nov 25-251.43%
Nov 25-267.39%
Nov 25-255.18%
Nov 25-280.98%
Oct 25-257.44%
Oct 25-244.61%
Oct 25-230.21%
Oct 25-210.59%
Oct 25-272.45%
Sep 25-260.19%
Sep 25-222.23%
Sep 25-280.38%
Sep 25-274.96%
Aug 25-238.24%
Aug 25-234.56%
Aug 25-272.3%
Aug 25-270.28%
Aug 25-282.81%
Jul 25-259.56%
Jul 25-189.81%
Jul 25-190.04%
Jul 25-145.96%
Jun 25-126.79%
Jun 25-75.79%
Jun 25-127.07%
Jun 25-120.79%
May 25-102.56%
May 25-108.22%
May 25-84.08%
May 25-77.81%
May 25-81.69%
Apr 25-62.09%
Apr 25-54.85%
Apr 25-72.04%
Apr 25-75.32%
Mar 25-33.73%
Mar 25-36.07%
Mar 25-53.97%
Mar 25-47.94%
Feb 25-43.2%
Feb 25-41.83%
Feb 25-40.17%
Feb 25-48.6%
Jan 25-47.45%
Jan 25-44.73%
Jan 25-45.77%
Jan 25-39.79%
Jan 25-47.64%
Dec 24-46.68%
Dec 24-51.15%
Dec 24-44.44%
Dec 24-46.23%
Nov 24-50.54%
Nov 24-40.68%
Nov 24-40.47%
Nov 24-40.8%
Nov 24-39.89%
Oct 24-36.04%
Price to Sales
01020304050med 15.64Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
IUGNF Price to Sales by quarter
PeriodPrice to Sales
Sep 2612.54
Sep 2612.54
Sep 2612.48
Aug 2620.08
Aug 2623.64
Aug 2624.17
Aug 2622.25
Jul 2620.8
Jul 2632.19
Jul 2622.53
Jul 2624.24
Jul 2625.98
Jun 2629.33
Jun 2630.42
Jun 2626.12
Jun 2633.48
May 2625.02
May 2628.69
May 2626.18
May 2627.91
May 2628.53
Apr 2633.63
Apr 2640.76
Apr 2632.62
Apr 2636.11
Mar 262.83
Mar 265.01
Mar 266.93
Mar 265.42
Feb 265.96
Feb 265.85
Feb 265.8
Feb 265.82
Jan 267.32
Jan 268.55
Jan 266.45
Jan 268.41
Jan 269.45
Dec 257.85
Dec 257.8
Dec 257.61
Dec 257.06
Nov 258.06
Nov 257.58
Nov 257.94
Nov 257.22
Oct 257.88
Oct 258.29
Oct 258.81
Oct 259.63
Oct 257.44
Sep 254.82
Sep 255.64
Sep 254.47
Sep 254.56
Aug 255.26
Aug 255.34
Aug 254.6
Aug 254.64
Aug 254.43
Jul 254.83
Jul 256.6
Jul 256.59
Jul 258.59
Jun 259.88
Jun 2516.54
Jun 259.86
Jun 2510.38
May 2512.22
May 2511.58
May 2514.9
May 2516.11
May 2515.34
Apr 2520.18
Apr 2522.85
Apr 2517.4
Apr 2516.64
Mar 2524.17
Mar 2522.61
Mar 2515.11
Mar 2517.01
Feb 2518.88
Feb 2519.5
Feb 2520.3
Feb 2516.78
Jan 2517.19
Jan 2518.23
Jan 2517.82
Jan 2520.49
Jan 2517.12
Dec 2417.47
Dec 2415.94
Dec 2418.35
Dec 2417.64
Nov 2416.13
Nov 2420.04
Nov 2420.15
Nov 2419.98
Nov 2420.44
Oct 2422.63
Price to Book
0246med 1.56Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
IUGNF Price to Book by quarter
PeriodPrice to Book
Sep 260.39
Sep 260.39
Sep 260.39
Aug 260.62
Aug 260.73
Aug 260.75
Aug 260.69
Jul 260.65
Jul 261
Jul 260.7
Jul 260.75
Jul 260.81
Jun 260.91
Jun 260.94
Jun 260.81
Jun 261.04
May 260.78
May 260.89
May 260.81
May 260.87
May 260.89
Apr 261.04
Apr 261.26
Apr 261.01
Apr 261.12
Mar 260.59
Mar 261.04
Mar 261.44
Mar 261.13
Feb 261.24
Feb 261.22
Feb 261.21
Feb 261.21
Jan 261.52
Jan 261.78
Jan 261.34
Jan 261.75
Jan 261.97
Dec 251.63
Dec 251.62
Dec 251.58
Dec 251.47
Nov 251.68
Nov 251.58
Nov 251.65
Nov 251.5
Oct 251.64
Oct 251.72
Oct 251.83
Oct 252
Oct 251.55
Sep 251
Sep 251.18
Sep 250.93
Sep 250.95
Aug 251.1
Aug 251.11
Aug 250.96
Aug 250.97
Aug 250.92
Jul 251.01
Jul 251.38
Jul 251.37
Jul 251.79
Jun 252.06
Jun 253.45
Jun 252.06
Jun 252.16
May 252.55
May 252.41
May 253.11
May 253.36
May 253.2
Apr 254.21
Apr 254.76
Apr 253.63
Apr 253.47
Mar 253.42
Mar 253.2
Mar 252.14
Mar 252.41
Feb 252.67
Feb 252.76
Feb 252.87
Feb 252.38
Jan 252.43
Jan 252.58
Jan 252.52
Jan 252.9
Jan 252.42
Dec 242.47
Dec 242.26
Dec 242.6
Dec 242.5
Nov 242.28
Nov 242.84
Nov 242.85
Nov 242.83
Nov 242.9
Oct 243.2
Imugene Limited
IUGNF
Stockpicker

Video analysis: IUGNF

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: IUGNF

Figma shares rise as Bank of America resumes coverage with a ‘Buy’ rating

proactiveinvestors.com · 7 Jul 2026

Figma shares rise as Bank of America resumes coverage with a ‘Buy’ rating

Figma (NYSE:FIG) was reinstated with a ‘Buy’ rating and a $30 price objective by Bank of America, with the firm arguing that artificial intelligence is...

Imugene raises $11.1 million to advance azer-cel after complete responses in early cohort

proactiveinvestors.com · 7 Jul 2026

Imugene raises $11.1 million to advance azer-cel after complete responses in early cohort

Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) is raising about A$11.12 million before costs through a two-tranche placement, strengthening its balance sheet as...

Shell flags 'significantly higher' gas trading and sells South Africa business - UPDATE

proactiveinvestors.com · 7 Jul 2026

Shell flags 'significantly higher' gas trading and sells South Africa business - UPDATE

Shell PLC (LSE:SHEL, NYSE:SHEL) shares jumped over 2% after it said stronger trading and improved refining margins should support second-quarter...

Imugene reports second BTKi cohort response - ICYMI

proactiveinvestors.com · 4 Jul 2026

Imugene reports second BTKi cohort response - ICYMI

Imugene Ltd (ASX:IMU, OTC:IUGNF) earlier this week reported a second complete response in the concurrent Bruton Tyrosine Kinase inhibitor, or BTKi, cohort...

Imugene CEO details azer-cel trial milestone - ICYMI

proactiveinvestors.com · 3 Jul 2026

Imugene CEO details azer-cel trial milestone - ICYMI

Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) earlier this week reported the first complete response in the concurrent Bruton Tyrosine Kinase inhibitor, or...

Anthropic clears export hurdle for Fable 5, easing a threat to its IPO story

proactiveinvestors.com · 1 Jul 2026

Anthropic clears export hurdle for Fable 5, easing a threat to its IPO story

The most striking thing about the standoff that ended on Tuesday is not that it ended, but that it happened at all: a US government blocking a US company...

Imugene reports second complete response in azer-cel BTKi cohort

proactiveinvestors.com · 1 Jul 2026

Imugene reports second complete response in azer-cel BTKi cohort

Just a day after reporting the first complete response in the concurrent Bruton Tyrosine Kinase inhibitor (BTKi) cohort of its ongoing Phase 1b azer-cel...

Fed may adopt leaner communications strategy under Warsh, says Deutsche Bank

proactiveinvestors.com · 1 Jul 2026

Fed may adopt leaner communications strategy under Warsh, says Deutsche Bank

Federal Reserve communications are likely to become shorter, less reliant on forward guidance and more focused on longer-term economic narratives under new...

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.